About Careers Internship MedBlog Contact us

Researchers Find Goserelin Beneficial in Preserving Fertility of Young Women Undergoing Chemo for Breast Cancer

by Kathy Jones on May 31, 2014 at 4:41 PM
 Researchers Find Goserelin Beneficial in Preserving Fertility of Young Women Undergoing Chemo for Breast Cancer

Goserelin can help preserve the fertility of young women who are undergoing chemotherapy for certain types of breast cancer, a new study reveals.

The cancer drug also appeared to improve survival, according to the results of a phase III clinical trial unveiled at the American Society for Clinical Oncology annual meeting.


Early menopause can be triggered by breast cancer chemotherapy. Some women resume menstruating after chemo and can have children, but many cannot.

"I think these findings are going to change our clinical practice," said senior study author Kathy Albain of Loyola University Medical Center.

Some 49,000 women under 50 are diagnosed with breast cancer each year in the United States, making up about a quarter of all breast cancer cases.

About 15 percent of young women have cancers that are hormone receptor negative, and these are the women who could benefit from taking goserelin to essentially put the ovaries at rest during chemo, researchers said.

The study randomly assigned 131 patients to receive standard chemotherapy and 126 to receive chemotherapy plus goserelin by injection once every four weeks.

Nearly half (45 percent) of the women on standard chemo stopped menstruating after two years.

Only 20 percent of the women receiving goserelin had stopped menstruating.

Pregnancies were twice as common in the goserelin group -- 21 percent compared to 11 percent.

And 89 percent of the women taking goserelin had no signs or symptoms of cancer four years later, compared to 78 percent of those receiving standard chemotherapy.

Survival was higher too -- 92 percent in the goserelin group and 82 percent in the standard chemo group.

Albain said women who need to undergo chemo for early breast cancer should consider taking goserelin to prevent premature ovarian failure.

Goserelin, known by the brand name Zoladex, was approved by the Food and Drug Administration for prostate cancer, certain benign gynecological disorders and certain breast cancers.

Source: AFP
Font : A-A+



Recommended Readings

Latest Cancer News

Oral Lipid Nanoparticle Drug Averts Colitis-Associated Cancer Development
Lipid nanoparticles use M13, a potent anti-ulcerative colitis compound, in an oral formulation to combat colitis-linked cancer.
Breast Reconstruction and Shorter Radiation: The Winning Combo!
Shorter radiation course is just as good as the regular one for women choosing breast reconstruction after mastectomy, saving time and money.
Innovative Cancer Implant Technology Holds Promise to Cut Death Rates by Half
HAMMR's small size permits minimally invasive implantation, monitoring cancer status, and dynamically adjusting immunotherapy, akin to a glucose monitor.
Personalized Vaccine and T Cell Therapy for Ovarian Cancer Patients
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Kinase-Targeted Therapy Revolutionizes Colorectal Cancer Care
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Researchers Find Goserelin Beneficial in Preserving Fertility of Young Women Undergoing Chemo for Breast Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests